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SYNOPSIS
Health care workers (HCWs) may transmit respiratory 
infection to patients. We assessed evidence for the 
effectiveness of vaccinating HCWs to provide indirect 
protection for patients at risk for severe or complicated 
disease after acute respiratory infection. We searched 
electronic health care databases and sources of gray 
literature by using a predefi ned strategy. Risk for bias 
was assessed by using validated tools, and results were 
synthesized by using a narrative approach. Seventeen of 
the 12,352 identifi ed citations met the full inclusion criteria, 
and 3 additional articles were identifi ed from reference or 
citation tracking. All considered infl uenza vaccination of 
HCWs, and most were conducted in long-term residential 
care settings. Consistency in the direction of effect was 
observed across several different outcome measures, 
suggesting a likely protective effect for patients in residential 
care settings. However, evidence was insuffi cient for us to 
confi dently extrapolate this to other at-risk patient groups.
Respiratory disease is a leading cause of deaths worldwide, and infl uenza and pneumococcal infections 
are major contributors. Certain groups, such as persons >65 
years of age or with chronic underlying health problems (1) 
are particularly vulnerable to severe respiratory disease and 
have poorer outcomes after infection than does the general 
population. These persons are likely to be frequent users 
of health care facilities, and outbreaks have been described 
in a range of high-risk environments, including acute care 
(2,3), pulmonary (4), and infectious diseases wards (5); 
organ transplant departments (6); children’s wards (7,8); 
neonatal intensive care units (9); and nursing homes 
(10,11). Severe respiratory infections often occur despite 
high vaccine coverage rates among patients, suggesting 
that seroconversion is suboptimal (10). Although the origin 
of infection often is diffi cult to establish, evidence from 
some outbreaks (5,7,10–14) suggests that transmission 
from HCWs to patients is likely.
 It is estimated from previous infl uenza seasons that 
≈20% of HCWs have evidence of infection (15), although 
not necessarily acquired in the workplace. Young healthy 
adults often have asymptomatic infection, and ≈28%–59% 
might experience subclinical infection (15). Many persons 
with mild or subclinical illness continue to work while 
infectious, and even when illness is recognized, virus might 
be shed before symptom onset. In a randomized controlled 
trial among health care professionals, Wilde et al. 
demonstrated that infl uenza vaccine was 88% effi cacious 
for reducing serologically confi rmed infl uenza A infection 
and 89% effi cacious for reducing serologically confi rmed 
infl uenza B infection (16). Therefore, vaccination of 
HCWs has been widely recommended to provide direct 
protection for themselves and indirect protection for their 
patients (1,17).
Despite efforts to encourage infl uenza vaccination 
of HCWs, coverage has been historically poor. Recently, 
ethical arguments for mandatory infl uenza vaccination 
have been raised that focus not only on the direct and 
indirect benefi ts to staff and patient health but also on 
the economic consequences. Burls et al. (18) suggested 
that at a cost of £51–£405 (US$85–$675) per life-year 
saved, mandatory vaccination is likely to be cost-effective. 
However, evidence for the effectiveness of vaccinating 
HCWs for protecting vulnerable patients is limited.
Two recent systematic reviews considered the evidence 
for indirect protection of vulnerable patient groups after 
staff infl uenza vaccination (18,19). They suggest that 
vaccination of HCWs might be effective for reducing death 
and infl uenza-like illness (ILI) among elderly residents, but 
we are unaware of comparable data related to other at-risk 
groups. We aimed to identify and assess further evidence 
for the effect of vaccinating HCWs on patient groups most 
vulnerable to severe or complicated respiratory illness.
Methods
The full study protocol is registered with the UK 
National Institute for Health Research International 
Prospective Register of Systematic Reviews (www.crd.york.
ac.uk/PROSPERO [registration no. CRD420111092]). We 
searched several electronic health care databases, sources 
of evidence-based reviews, guidelines, and gray literature 
in accordance with the specifi cations of each database 
(Figure). In addition, we contacted domain experts and 
vaccine manufacturers to identify unpublished data and 
undertook citation and reference tracking for all included 
papers. Thesaurus-indexed and free text terms were defi ned 
for the population, intervention, and outcome parameters; 
peer reviewed; and adapted as necessary for each search 
engine.
Eligibility criteria were defi ned a priori as follows:
• Types of study: any experiment, observational study, 
or systematic review reporting on the effectiveness 
of vaccination (including infl uenza or pneumococcal 
vaccines) of HCWs for protecting patients at higher 
risk for severe or complicated respiratory infection.
• Types of participants: persons at higher risk for 
severe or complicated illness as a result of acute 
respiratory infection (as defi ned in World Health 
Organization [1] and Advisory Committee on 
Immunization Practices guidance [17]), who have 
received or are receiving care from an HCW.
• Types of intervention: infl uenza or pneumococcal 
vaccination of any worker providing medical, 
nursing, social, or personal health care (because no 
uniformly accepted defi nition of an HCW exists, it 
1226 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 8, August 2012
Vaccination of Health Care Workers
was defi ned by the peer-reviewed terms specifi ed in 
the search strategy).
• Types of outcome measure: cases or consultations, 
death or hospitalization for acute respiratory disease, 
infl uenza, ILI, or pneumococcal disease.
Published and unpublished reports from any year 
that were written in Chinese, English, French, Japanese, 
Portuguese, Russian, or Spanish were considered. A 
3-stage process was used to assess eligibility for inclusion 
screening fi rst by title, then abstract, and then full text. 
Two reviewers undertook this in parallel for stages 1 and 2 
and independently for stage 3. Consensus was reached by 
discussion; when reviewers disagreed, a third reviewer was 
consulted for a fi nal decision. Where multiple reports were 
identifi ed for the same piece of original research, the most 
recent peer-reviewed source was selected.
Two reviewers independently extracted data from each 
included, by using a predefi ned, piloted template. The risk 
for bias was assessed by using the Cochrane Collaboration 
tool (20) for experimental and prospective cohort studies, 
the Downs and Black tool (21) for other observational 
studies, and the US Agency for Healthcare Research 
and Quality (22) domain and element-based evaluation 
instrument for systematic reviews. Again, consensus was 
reached by discussion, with engagement of a third reviewer 
as necessary. No additional information was sought from 
corresponding authors. Data were synthesized qualitatively 
by using a narrative approach in accordance with the 
framework described by the Economic and Social Research 
Council and recommended by the University of York 
Centre for Reviews and Dissemination (23).
Results
Study Selection
We identifi ed 12,352 citations (Figure): 10,713 from 
health care databases and the remainder from additional 
sources. Seventeen studies met the inclusion criteria 
at the full text stage; 3 others were identifi ed from 
citation or reference tracking. Of these, 14 were primary 
research articles; 4 were cluster randomized controlled 
trials (RCTs), and 10 were observational studies. Four 
of the remaining 6 articles were different versions of a 
report relating to 1 systematic review, and the other 2 
were different versions of a report relating to a second 
systematic review. One of these systematic reviews (18) 
provided a qualitative analysis of 2 of the earliest cluster 
RCTs (24,25), and the other (19) provided a quantitative 
meta-analysis of all 4 cluster RCTs (24–27) and 1 
additional observational study (28). We used the most 
recent and detailed version of each review published in a 
peer-reviewed source in this study.
All of the primary studies considered infl uenza 
vaccination of HCWs (online Appendix Table 1, wwwnc.
cdc.gov/EID/article/18/8/11-1355-TA1.htm); therefore, we 
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Figure. Study selection for a review of the 
vaccination of health care workers to protect 
patients at risk for acute respiratory disease.
SYNOPSIS
discarded our planned subanalysis relating to pneumococcal 
vaccination. Only 4 studies (24–26,29) defi ned HCW, even 
though this defi nition is likely to affect the probability 
of transmission and therefore the magnitude of observed 
effects. Where reported, vaccination among staff ranged 
from ≈35% to 70% in the intervention arm and from none 
to 32% in the control arm of experimental studies and 
from 12% to 90% in observational studies. Eleven of the 
primary research studies were conducted in long-term care 
facilities; the remainder were conducted in renal dialysis 
facilities (30), a pediatric hospital (31), and an adult 
oncology hospital (32) (1 study each). Where reported, 
vaccination coverage among patient populations ranged 
from 0% to ≈90%, and few studies considered additional 
infection control practices, such as hand washing, duration 
of contact, or use of face masks, which vary and again 
infl uence the propensity for transmission.
Risk for Bias
Cochrane Collaboration Tool
Concerns arose largely from the lack of blinding of 
participants or study personnel (Table 1). Although the effect 
was likely to be minimal with regard to the primary outcome 
for all 4 RCTs (all-cause mortality), it might have resulted 
in underestimation or overestimation of additional, more 
subjective, outcome measures, such as incidence of ILI.
All studies, except for that by Lemaitre et al. (26), were 
judged to be at some further risk for bias. This included 
selection bias (inadequate description of selection criteria 
[24,25,33] or sequence allocation [25,28,33]), performance 
bias (lack of detail about allocation concealment [25,26]), 
and measurement bias (no clearly defi ned outcome measure 
[28]).
Downs and Black Tool
The Downs and Black tool (Table 2) considers 5 
assessment domains, but because most observational 
studies identifi ed were primarily descriptive, we excluded 
the power domain in this review. Scores ranged from 3/27 
(34) to 10/27 (29,30,35), with higher scores representing 
lower risk for bias. None of the studies provided suffi cient 
detail about the patient population, and only 1 (29) described 
principal confounders. Other concerns about reporting 
related to lack of detail of study objectives (29,32,34), a 
priori defi nition of outcome measures (32,34–37) or those 
lost to follow up (35), failure to provide suffi cient detail of 
statistical analysis (29,30,34–37), lack of randomization or 
blinding, and failure to adjust outcome measures.
Agency for Healthcare Research and Quality Tool
We assessed the 2 identifi ed systematic reviews 
(18,19) by using the Agency for Healthcare Research and 
Quality tool (22). Both appeared to be at a comparatively 
low risk for bias, providing a clearly defi ned research 
question, search strategy, inclusion and exclusion criteria, 
and description of outcomes. However, details were lacking 
about blinding of reviewers to authorship and measurement 
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Table 1. Risk for bias assessed by using the Cochrane Collaboration tool in a review of the vaccination of health care workers to
protect patients at risk for acute respiratory disease* 
Study 
Sequence
generation 
Allocation
concealment
Blinding of participants, personnel 
and outcome assessors 
Incomplete outcome 
data Selective
outcome
reporting 
Other
sources 
of bias 
Primary 
outcome
Secondary 
outcomes
Primary 
outcome
Secondary 
outcomes
Lemaitre et al. (26)
Hayward et al. (27)
Carman et al. (24)
Potter et al. (25)
Saito et al. (33)
Oshitani et al. (28)
*Black shading, low risk of bias; light gray shading, uncertain risk of bias; dark gray shading, high risk of bias; blank cells, no secondary outcome measure 
reported. 
Table 2. Risk for bias by using the Downs and Black tool in a review of the vaccination of health care workers to protect patients at risk 
for acute respiratory disease 
Study 
Type of score (maximum score)* 
Reporting (11) 
External validity 
(3) 
Internal validity, 
bias (7) 
Internal validity, 
confounding (6) Total (27) 
Ando et al. (30) 5 2 2 1 10 
Shugarman et al. (35) 6 0 1 3 10 
Kanaoka et al. (29) 5 1 3 1 10 
Monto et al. (36) 5 0 2 2 9 
Weinstock et al. (32) 4 0 4 1 9 
Stevenson et al. (37) 4 1 2 1 8 
Munford et al. (34) 2 0 0 1 3 
*Maximum score indicates lowest risk of bias for each domain. 
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of agreement in extracting data, which might have resulted 
in measurement bias.
Synthesis of Results
Cases or Consultations for Acute Respiratory 
Disease
One RCT reported data (25) for 2 measures of con-
sultation for respiratory disease; episodes of lower res-
piratory tract infection and suspected viral illness (Table 3). 
In addition, the estimate for lower respiratory tract infection 
was adjusted for clustering by Thomas et al. (19). Both 
measures demonstrated reduced odds, and results were 
signifi cant for suspected viral illness when vaccinated and 
nonvaccinated patients were considered together.
The study by Potter et al. (25) was considered to be at a 
higher risk for bias than the other RCTs identifi ed; thus, the 
strength of evidence for these outcomes is questionable. In 
addition, the measures considered are nonspecifi c, and the 
observed effects cannot necessarily be attributed to reduced 
infl uenza infection. Nasopharyngeal samples were taken 
from a subset of patients within 48 hours after symptoms 
developed; no samples were positive for infl uenza on 
immunofl uorescence assay.
Cases or Consultations for Infl uenza or ILI
Data were reported in 13 studies for 5 outcome 
measures of infl uenza/ILI. Eight primary studies measured 
clinically defi ned infl uenza/ILI (online Appendix Table 2, 
wwwnc.cdc.gov/EID/article/18/8/11-1355-TA2.htm; 
Table 4).
Three RCTs (25–27) measured cases of ILI, and these 
data were pooled by Thomas et al. (19) to demonstrate a 
statistically signifi cant reduction in odds. Two observational 
studies (28,33) also measured cases of clinically defi ned 
ILI, demonstrating statistically signifi cant reductions in 
risk, although the threshold of staff vaccination coverage 
used to categorize facilities in these studies varied (Oshitani 
[28] considering facilities where more or fewer than 10 staff 
were vaccinated, and Saito [33] comparing facilities with 
<40%, 40%–59%, and >60% coverage among staff). A third 
observational study (29) reported no correlation between 
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Table 3. Cases of and consultations for acute respiratory disease in a review of the vaccination of health care workers to protect
patients at risk for acute respiratory disease* 
Outcome measure (study) Study design Method of assessment 
Measure of effect in patient 
population
Effect estimate 
(95% CI) 
Clinically defined episodes 
of viral illness (Potter et al. 
[25])
Cluster RCT Not defined. No. episodes recorded 
by study nurses. 
OR, nonvaccinated and 
vaccinated patients 
0.64 (0.48–0.87) 
OR, vaccinated patients 0.40 (0.26–0.62) 
OR, nonvaccinated patients 0.98 (0.65–1.48) 
Lower respiratory tract infection    
 Potter et al. (25) Cluster RCT Defined as 1) pulmonary crackles, 
wheeze, or tachypnea plus 
temperature >37.0°C or leukocyte 
count >10 × 109/L or 2) a positive 
sputum culture. No. episodes 
recorded by study nurses. 
OR, nonvaccinated and 
vaccinated patients 
0.69 (0.40–1.19) 
   OR, vaccinated patients 0.59 (0.25–1.38) 
   OR, nonvaccinated patients 0.77 (0.38–1.57) 
 Thomas et al. (19) Pooled data  OR, adjusted for clustering 0.71 (0.29–1.71)† 
*RCT, randomized controlled trial; OR, odds ratio. Boldface indicates statistical significance. 
†p = 0.44. p value not reported for other categories. 
Table 4. Clinically defined outbreaks and clusters of ILI in a review of the vaccination of health care workers to protect patients at risk 
for acute respiratory disease* 
Study Study design Method of assessment 
Measure of effect in patient 
population
Effect estimate 
(95% CI) 
Oshitani et al. (28) Prospective 
cohort 
Defined as ILI >10% of total resident 
population. Mandatory reporting by 
survey. 
OR, unadjusted facilities with 
>10 staff members vaccinated 
vs. those with <10 staff 
members vaccinated 
0.30 (0.09–0.69)† 
Stevenson et al. (37) Cross-
sectional
No definition provided. Reporting by 
survey. 
Ȥ2 test for trend; logistic 
regression 
Ȥ2 p = 0.03; logistic 
regression p = 0.08 
Shugarman et al. (35) Cross-
sectional
Defined as >3 residents within a 72-h 
period with influenza-like symptoms, 
sudden onset of fever, or 
“feverishness” and >1 of the following 
respiratory symptoms; sore throat, 
runny nose, cough, or nasal 
congestion. Reporting by survey. 
OR, facilities with staff 
vaccination coverage >55% and 
patient vaccination coverage 
>89%, vs. those with lower 
coverage
0.39 (0.17–0.87)† 
*ILI, influenza-like illness; OR, odds ratio. Boldface indicates statistical significance. 
†p value not reported. 
SYNOPSIS
staff vaccination coverage and cases of infl uenza in patients, 
although the relative change in vaccination coverage (79%–
91%) was small and thus any difference in the number of 
cases was probably diffi cult to detect. The magnitude of 
reported effects varied, most notably by infl uenza season in 
the study of Hayward et al. (27), and with patient vaccination 
status in the study of Potter et al. (25).
One study measured general practitioners consultations 
for ILI (27). An inconsistent effect was demonstrated 
across different periods of infl uenza activity, but pooled 
data suggested an overall statistically signifi cant reduction 
in the odds of consultation after vaccination of HCWs.
Three observational studies (28,35,37) demonstrated a 
statistically signifi cant protective effect of staff vaccination 
against clinically defi ned outbreaks of ILI in patients (Table 
4). The thresholds used to categorize facilities on the basis 
of staff vaccination coverage again varied among studies, 
and these data were considered to be at relatively high risk 
for bias.
Measures of laboratory-confi rmed infection (online 
Appendix Table 3, wwwnc.cdc.gov/EID/article/18/8/11-
1355-TA3.htm) were less frequently reported and generally 
based on small samples of data at high risk for bias. 
Five studies measured laboratory-diagnosed infl uenza 
(24,25,31,32,36), although 1 reported no statistical analysis 
(25). Different methods of defi ning laboratory confi rmation 
were used (online Appendix Table 3). Thomas et al. (19) 
pooled data from the 2 RCTs (24,25) to demonstrate a small 
nonsignifi cant protective effect. This result is supported by 
evidence from 2 additional observational studies (31,32), 
which indicated a statistically signifi cant reduction in the 
proportion of laboratory-confi rmed cases of nosocomial 
infl uenza among inpatient pediatric and oncology patients 
after implementation of vaccination campaigns. In addition, 
Monto et al. (36) measured outbreaks of laboratory-diagnosed 
infl uenza, and this was the only study not to demonstrate a 
protective effect of vaccinating HCWs. The authors reported 
a higher, but nonsignifi cant, median vaccination coverage 
among staff in homes experiencing outbreaks.
Deaths from Respiratory Infection, ILI, or Acute 
or Respiratory Disease or Its Complications
Evidence for 5 measures of death was identifi ed 
(Table 5). All 4 RCTs (24–27) considered all-cause death 
as their primary objective, providing the strongest evidence 
on the basis of study design. Although not defi ned a priori as 
an outcome of interest for this review, data were therefore 
extracted. These were pooled by Thomas et al. (19) to 
demonstrate a statistically signifi cant protective effect.
Although at higher risk for bias, supporting data were 
provided for 4 more-specifi c measures. Thomas et al. 
(19) pooled data from 2 RCTs, 1 measuring deaths after 
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Table 5. Measures of death in a review of the vaccination of health care workers to protect patients at risk for acute respiratory 
disease* 
Outcome measure and 
study Study design 
Method of 
assessment Measure of effect in patient population Effect estimate (95% CI), p value
All-cause mortality     
 Potter et al. (25) Cluster RCT Death 
certificate 
OR, vaccinated and nonvaccinated patients 0.56 (0.40–0.80)† 
OR, vaccinated patients 0.57 (0.35–0.91)† 
OR, nonvaccinated patients 0.56 (0.34–0.94)† 
 Carman et al. (24) Cluster RCT Not stated OR 0.62 (0.36–1.04), p = 0.092 
 Hayward et al. (27) Cluster RCT Reporting by 
lead nurse 
Rate difference, epidemic period 1 –0.05 (–0.07 to –0.02), p = 0.002
Rate difference, epidemic period 2 –0.01 (–0.04 to 0.02), p = 0.49 
Rate difference, nonepidemic period 1 0.00 (–0.03 to 0.03), p = 0.93 
Rate difference, nonepidemic period 2 0.01 (–0.03 to 0.04), p = 0.70 
 Lemaitre et al. (26) Cluster RCT Not stated OR 0.86 (0.72–1.02), p = 0.08 
 Thomas et al. (19) Pooled data  OR, adjusted for clustering 0.68 (0.55–0.84), p<0.001 
Respiratory deaths: 
Lemaitre et al. (26)
Cluster RCT Reporting by 
study nurses
OR 1.55 (0.59–4.10), p = 0.38 
Pneumonia-associated deaths    
 Potter et al. (25) Cluster RCT Reporting by 
lead nurse 
OR, vaccinated and nonvaccinated patients 0.60 (0.37–0.97)† 
OR, vaccinated patients 0.56 (0.28–1.13)† 
OR, nonvaccinated patients 0.64 (0.33–1.23)† 
 Thomas et al. (19) Pooled data  Risk ratio, adjusted for clustering 0.87 (0.47–1.64), p = 0.67 
Death with influenza-like illness    
 Hayward et al. (27) Cluster RCT Reporting by 
lead nurse 
Rate difference, epidemic period 1 –0.01 (–0.02 to 0.01), p = 0.24 
Rate difference, epidemic period 2 –0.01 (–0.03 to 0.00), p = 0.08 
Rate difference, nonepidemic period 1 –0.01 (–0.04 to 0.02), p = 0.59 
Rate difference, nonepidemic period 2 0.01 (–0.01 to 0.02), p = 0.35 
 Thomas et al. (19) Pooled data  OR, adjusted for clustering 0.72 (0.31–1.70), p = 0.45 
Laboratory-diagnosed 
influenza at death: 
Carman et al. (24)
Cluster RCT Nasal swab 
within 12 h 
before death 
Difference in proportions, influenza positive 
at death 
20%, p = 0.055 
*RCT, randomized controlled trial; OR, odds ratio. Boldface indicates statistical significance. Shaded fields represent pooled data. 
†p value not reported. 
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pneumonia (25), the other measuring respiratory deaths 
(26), and demonstrated a small nonsignifi cant protective 
effect. However, the validity of this pooled analysis was 
questionable because how these outcomes were defi ned 
was not clear. Nonsignifi cant reductions in risk also 
were observed for laboratory-diagnosed infl uenza at 
death (24) and death after ILI (27). Again, the direction 
of the observed effects was largely consistent with other 
measures, providing further support for a hypothesis of 
indirect protection.
Admission to a Health Care Facility or Any Other 
Suggestion of Impact
Hospitalization was measured in 2 RCTs (26,27), 
pooled data suggesting a small, nonsignifi cant effect 
(Table 6). One RCT also measured hospitalization for 
respiratory causes (26) and 1 admission to hospital with ILI 
(27), although neither demonstrated any apparent effect. 
This result is particularly noteworthy given the observed 
decrease in deaths and might refl ect health-seeking 
behaviors.
Discussion
Evidence is limited for the effectiveness of 
vaccination of HCWs for protecting patients at higher 
risk for severe or complicated respiratory illness. Despite 
the broad question posed, extensive searching, and large 
number of resultant hits, our search resulted in a low 
yield of studies, all of which focused on infl uenza with no 
consideration for pneumococcal infection. This fi nding is 
perhaps not surprising because pneumococcal vaccination 
is not routinely recommended for HCWs and little, if 
any, evidence exists of nosocomial spread. A consistent 
direction of effect was observed across multiple outcome 
measures, with virtually all studies noting a trend toward 
a protective effect of vaccinating HCWs. This consistency 
adds to the degree of confi dence in interpreting our 
overall fi ndings. Given that most studies were carried out 
in long-term care facilities, we conclude that vaccination 
of HCWs against infl uenza is likely to offer protection 
for this patient group. However, future reviews that 
specifi cally examine the effect of vaccinating other 
outpatient providers, such as home HCWs and hospital 
staff in acute care, short-stay settings, would clearly be 
of value. These fi ndings are more diffi cult to extrapolate 
to other at-risk groups, although some, albeit limited, 
evidence was identifi ed from other settings to suggest a 
similar effect.
The results of all 4 RCTs (24–27) and 1 of the 
observational studies identifi ed (28) previously had been 
pooled in a quantitative meta-analysis (19). The authors 
of this analysis concluded that evidence is lacking that 
vaccinating HCWs prevents infl uenza infection in elderly 
patients because the apparent benefi ts were confi ned to 
nonspecifi c outcome measures. We considered additional 
observational data that demonstrate consistency in the 
direction of the observed effects across specifi c and 
nonspecifi c outcome measures. Although the strength of 
evidence for more-specifi c measures is generally much 
weaker, these fi ndings add greater weight to the hypothesis 
of a potential protective effect.
The recent position statement by the Society for 
Healthcare Epidemiology of America (38) suggests that 
further studies are not needed because the biological 
rationale for vaccination does not vary by practice setting. 
However, effect size might vary considerably because of 
patient characteristics and care patterns (staff deployment 
and duration of inpatient stay), and further evidence is 
needed among the most at-risk groups where benefi ts are 
probably greatest, to enable prioritization of resources, 
particularly where vaccine shortages or resource limitations 
might exist.
Previous authors have suggested that vaccination 
of HCWs might enable development of herd immunity. 
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Table 6. Measures of hospitalization in a review of the vaccination of health care workers to protect patients at risk for acute
respiratory disease* 
Outcome measure and 
study Study design 
Method of 
assessment Measure of effect in patient population Effect estimate (95% CI) 
Hospitalization     
 Hayward et al. (27) Cluster RCT Reporting by 
lead nurse 
Rate difference, epidemic period 1 0.02 (0.05 to 0.02), p = 0.35 
Rate difference, epidemic period 2 0.00 (0.03 to 0.04), p = 0.84 
Rate difference, nonepidemic period 1 0.00 (0.04 to 0.03), p = 0.80 
Rate difference, nonepidemic period 2 0.00 (0.03 to 0.03), p = 0.86 
 Lemaitre et al. (26) Cluster RCT Not stated OR 1.03 (0.76–1.40), p = 0.85 
 Thomas et al. (19) Pooled data  OR, adjusted for clustering 0.90 (0.66 to 1.21), p = 0.47 
Hospitalization for 
respiratory causes: 
Lemaitre et al. (26)
Cluster RCT Not stated OR 1.01 (0.43–2.34), p = 0.98 
Admissions to hospital with 
influenza-like illness: 
Hayward et al. (27)
Cluster RCT Reporting by 
lead nurse 
Rate difference, epidemic period 1 0.02 (0.03 to 0.00), p = 0.009 
Rate difference, epidemic period 2 0.00 (0.02 to 0.02), p = 0.99 
Rate difference, nonepidemic period 1 0.01 (0.02 to 0.01), p = 0.32 
Rate difference, nonepidemic period 2 0.01 (0.00–0.02), p = 0.31 
*RCT, randomized controlled trial; OR, odds ratio. Boldface indicates statistical significance. Shading indicates pooled data. 
SYNOPSIS
Realistically, herd immunity is diffi cult to achieve in health 
care settings, especially acute care short-stay settings, 
because of patient admissions and discharges, visitors, 
and staff turnover. That said, herd immunity might not be 
necessary to benefi t patients; modeling studies (39) suggest 
a direct association between coverage and attack rates. 
Such studies (39) also suggest variation in the potential for 
transmission of infection by different staff groups, which 
should be explored in further detail.
This fi eld of research has some inherent problems. 
These diffi culties result in part from the diffi culty of 
isolating the effect of HCW vaccination, disentangling it 
from other factors that might infl uence patient outcomes, 
such as patient vaccination (as demonstrated by Potter et al. 
[25]) and background infl uenza activity (as demonstrated 
by Hayward et al. [27]). Staff vaccination itself might 
be linked to additional confounding variables, such as 
organizational culture and professional beliefs. In fact, 
such confounding might explain the difference in fi ndings 
between the work of Monto (36) and the other authors. 
Prospective collection of information relating to relevant 
transmission factors and infection control measures that 
were largely overlooked by the studies in this review should 
be used to enable appropriate adjustment in future studies. 
Furthermore, the most appropriate outcome measures are 
diffi cult to defi ne because not all persons with laboratory-
confi rmed infection have symptoms of illness and vice 
versa. Future studies thus need to demonstrate consistent 
effects for a range of clearly defi ned outcomes by using 
valid measures across several different infl uenza seasons, 
with suffi cient power to detect true underlying effects.
The fi ndings of our review are subject to several 
limitations. Because 11 of the 14 primary research 
articles considered outcomes in long-term care facilities, 
generalizability to other at-risk groups is limited. In addition, 
we did not attempt to contact authors of original studies, 
and the conclusions drawn are limited by the reported 
detail. Although the number of reviewers was limited as far 
as possible, some inconsistency might have occurred in the 
selection, extraction, and assessment of data introducing 
potential bias, particularly where the opportunity for 
subjective judgment existed. We attempted to minimize 
inconsistency by using several standard assessment tools, 
but their use was limited by lack of information where 
components were not conducted because of the nature of 
the study design. Meta-analysis of the 4 RCTs identifi ed 
had already been conducted, and although we identifi ed 
additional observational data, the observed heterogeneity 
limited any further quantitative analysis.
Some wider possible effects of HCW vaccination, 
such as reduction in absenteeism because of illness, are 
beyond the scope of this review. Ethically, autonomy 
needs to be balanced with nonmalefi cence, and this 
need must be addressed when policy decisions about 
vaccination are considered. Anikeeva et al. (40) reported 
that in a review of 15 studies focusing on the reasons staff 
accept infl uenza vaccine, self-protection was the most 
important. However, patient protection also was perceived 
as important, particularly among HCWs in settings with 
higher risk patients (40). Nevertheless, HCWs would 
be justifi ed in claiming that the current evidence base 
is not especially strong and heavily weighted toward 
the benefi ts to patients receiving care in long-term care 
facilities, although limited evidence would not necessarily 
legitimize nonacceptance.
The existing evidence base is suffi cient to sustain 
current recommendations for vaccinating HCWs on the 
grounds that some protection of high-risk patients against 
infl uenza seems likely. However, vaccination should 
be considered 1 element of a broad package of infection 
prevention and control measures, such as good hand and 
respiratory hygiene, environmental cleaning, protection 
against respiratory droplets, and cohorted care during 
outbreaks. Well-designed studies that strengthen the 
evidence base might increase compliance with guidelines, 
resulting in improved coverage.
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